ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions. The company is involved in the development of neffy, a needle-free and low-dose intranasal epinephrine nasal spray for rescue medication for people with Type I severe allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. The company was founded in 2015 and is headquartered in San Diego, California. Show more

Location: 11682 El Camino Real, San Diego, CA, 92130, United States | Website: https://ars-pharma.com | Industry: Biotechnology | Sector: Healthcare

Market Cap

700.3M

52 Wk Range

$6.95 - $18.90

Previous Close

$7.08

Open

$7.09

Volume

1,865,799

Day Range

$6.94 - $7.40

Enterprise Value

510.4M

Cash

288.2M

Avg Qtr Burn

-21.34M

Insider Ownership

16.83%

Institutional Own.

87.55%

Qtr Updated

09/30/25

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
neffy® (epinephrine nasal spray) Details Anaphylaxis, Allergic Reactions (type I)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
neffy® (epinephrine nasal spray) Details Anaphylaxis, Allergic Reactions (type I)	Approved Quarterly sales	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
neffy® (epinephrine nasal spray) Details Acute flares in patients with chronic spontaneous urticaria	Phase 2b Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
SBT6050 (TLR8 Agonist) Details Cancer, Breast cancer	Failed Discontinued	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.